Pilot Opened Trial in HIV-infected Patients Including an Investigational Marketed Product
Status:
Completed
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
This study aims to provide new knowledge about the pathogenesis of HIV infection,
specifically, the role that immune activation and apoptotic activity play in immune recovery,
and in particular, in the paradoxical immunologic response of some patients on antiretroviral
therapy despite achievement of sustained and complete viral suppression. In this regard, the
investigators will prospectively evaluate the impact of intensification with Raltegravir in
those "discordants" patients with high index of immune activation, measured as the percentage
of CD8+HLADR+CD38+ cells. This will provide relevant information on the effectiveness of this
drug in guided intensification regimens.